Key Developments: Affymetrix Inc (AFFX.O)

AFFX.O on Nasdaq

10.86USD
3 Aug 2015
Change (% chg)

-- (--)
Prev Close
$10.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
780,849
52-wk High
$13.11
52-wk Low
$7.00

Search Stocks

Latest Key Developments (Source: Significant Developments)

Affymetrix Inc raises FY 2014 guidance
Thursday, 30 Oct 2014 04:00pm EDT 

Affymetrix Inc:Is raising FY 2014 guidance to total revenue of $345 million.FY 2014 adjusted EBITDA of about 17 pct of revenue.FY 2014 revenue of $342 mln, EBITDA of $44.3 mln - Thomson Reuters I/B/E/S.  Full Article

Affymetrix Inc and Ariosa Diagnostics announce signing of multi-year supply agreement in support of Ariosa's Non-Invasive Prenatal Test
Thursday, 16 Oct 2014 06:30am EDT 

Affymetrix Inc and Ariosa Diagnostics Inc:Announced the signing of a multi-year supply agreement covering Affymetrix arrays and instruments to be utilized as part of Ariosa's Harmony Non-Invasive Prenatal Test (NIPT).Says the partnership enables Ariosa to pursue the development of a Harmony test kit that will allow other laboratories around the world to adopt and perform this test.  Full Article

Affymetrix Inc raises FY 2014 guidance
Thursday, 31 Jul 2014 04:00pm EDT 

Affymetrix Inc:Raised FY 2014 guidance to total revenue of $340 mln and EBITDAO in the range of 14- 15 pct of revenue.FY 2014 revenue of $339 mln, EBITDA of $41.35 mln - Thomson Reuters I/B/E/S.  Full Article

Affymetrix, Inc and Leica Biosystems Announce the Launch of Fully Automated RNA
Thursday, 8 May 2014 05:30am EDT 

Affymetrix, Inc:Affymetrix, Inc and Leica Biosystems launches Affymetrix' fully automated RNA in situ hybridization assays ViewRNA eZ Assays on Leica BOND RX staining platform.These assays detect coding RNA as well as novel non-coding markers in formalin-fixed paraffin-embedded (FFPE) tissues.Dedicated for research use only, assays provide researchers with powerful automated solution for drug discovery, translational research, and development of new diagnostic tests for personalized medicine.Automation significantly reduces hands-on time and assay run time for profiling single-cell gene expression.  Full Article

Affymetrix, Inc reaffirms FY 2014 guidance - Conference Call
Thursday, 1 May 2014 05:00pm EDT 

Affymetrix, Inc:Says it remain committed to achieving revenue and EBITDA targets for FY 2014.FY 2014 revenue of $336 million and EBITDA of $46 million - Thomson Reuters I/B/E/S.  Full Article

Enzo Biochem announces settlement agreement with Affymetrix
Thursday, 24 Apr 2014 09:45am EDT 

Enzo Biochem Inc:Enters into settlement with Affymetrix, Inc. with respect to actions between the company and Affymetrix before the U.S. District Court.In settlement of the aforementioned cases, Affymetrix will pay $5,100,000.  Full Article

CollabRx and Affymetrix partner to develop analytical tools
Wednesday, 16 Apr 2014 09:05am EDT 

CollabRx Inc:Partners with Affymetrix to optimize the use of CollabRx's Genetic Variant Annotation (GVA) Service(tm) in connection with Affymetrix' OncoScan(tm) FFPE Assay Kit and CytoScan Cytogenetics Suite for analysis of gene copy number variation (CNV) in cancer research.Overall objective of the partnership is to enable the GVA Service to accept and process gene CNV data directly from OncoScan assays and CytoScan assays to provide scientific knowledge for biomarker CNV profiles in cancer.  Full Article

Affymetrix Inc gives FY 2014 guidance; EBITDA guidance above analysts' estimates - Conference Call
Wednesday, 5 Feb 2014 05:00pm EST 

Affymetrix Inc:Expects FY 2014 top-line revenue to be about $335 million.Expects FY 2014 EBITDA in the range of 12pct to 13pct.The company reported EBITDA of $52.64 million.FY 2014 revenue of $334 million and EBITDA of $49.9 million - Thomson Reuters I/B/E/S.  Full Article

Affymetrix Inc receives FDA Clearance of First-of-its-kind postnatal test for developmental delays and intellectual disabilities in children
Tuesday, 21 Jan 2014 06:00am EST 

Affymetrix Inc:Says it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its CytoScan Dx Assay.Says this assay is intended for the postnatal detection of DNA copy number variants (CNV) in patients referred for chromosomal testing.Says CytoScan Dx Assay is designed to help physicians diagnose children`s developmental and intellectual disabilities more comprehensively by enabling a high-resolution genome-wide analysis of genetic aberrations.Says high resolution analysis can reveal small aberrations not readily seen using traditional techniques.  Full Article

University of Bristol Collaborates with Affymetrix on Genotyping Arrays for Guaranteed Sustainability of Wheat Production
Monday, 13 Jan 2014 05:00am EST 

Affymetrix Inc:Says that they have collaboratively designed a wheat genotyping array and analyzed data from experiments as part of an effort to understand wheat genetics and breeding with a goal of ensuring guaranteed sustainable production.  Full Article

Search Stocks